Taysha Gene Therapies, Inc. — Investor Relations & Filings

Taysha Gene Therapies, Inc. is a clinical-stage company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies. The company's primary mission is to eradicate severe and life-threatening monogenic diseases that affect the central nervous system (CNS). Its therapeutic approach involves using AAV vectors to deliver functional genes to target cells, addressing the root cause of genetic disorders. Taysha maintains a pipeline of gene therapy programs in various stages of development. A key candidate, TSHA-102, is being investigated for the treatment of Rett syndrome and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.